Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Improving the management of candidemia through antimicrobial stewardship interventions.

Reed EE, West JE, Keating EA, Pancholi P, Balada-Llasat JM, Mangino JE, Bauer KA, Goff DA.

Diagn Microbiol Infect Dis. 2014 Feb;78(2):157-61. doi: 10.1016/j.diagmicrobio.2013.11.012. Epub 2013 Nov 15.

PMID:
24316015
2.

Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia.

Huang AM, Newton D, Kunapuli A, Gandhi TN, Washer LL, Isip J, Collins CD, Nagel JL.

Clin Infect Dis. 2013 Nov;57(9):1237-45. doi: 10.1093/cid/cit498. Epub 2013 Jul 29.

PMID:
23899684
3.

Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia.

Antworth A, Collins CD, Kunapuli A, Klein K, Carver P, Gandhi T, Washer L, Nagel JL.

Pharmacotherapy. 2013 Feb;33(2):137-43. doi: 10.1002/phar.1186. Epub 2013 Jan 25.

4.

Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients.

Davis SL, Vazquez JA, McKinnon PS.

Ann Pharmacother. 2007 Apr;41(4):568-73. Epub 2007 Mar 20.

PMID:
17374623
5.

[Evaluation of epidemiological characteristics and risk factors of candidemia in adult patients in a tertiary-care hospital].

Yenigün Koçak B, Kuloğlu F, Doğan Çelik A, Akata F.

Mikrobiyol Bul. 2011 Jul;45(3):489-503. Turkish.

PMID:
21935782
6.

Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.

Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM.

Clin Infect Dis. 2009 Jun 15;48(12):1695-703. doi: 10.1086/599039.

PMID:
19441981
7.

Impact of a rapid peptide nucleic acid fluorescence in situ hybridization assay on treatment of Candida infections.

Heil EL, Daniels LM, Long DM, Rodino KG, Weber DJ, Miller MB.

Am J Health Syst Pharm. 2012 Nov 1;69(21):1910-4. doi: 10.2146/ajhp110604.

PMID:
23111676
8.

Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain.

Bassetti M, Merelli M, Righi E, Diaz-Martin A, Rosello EM, Luzzati R, Parra A, Trecarichi EM, Sanguinetti M, Posteraro B, Garnacho-Montero J, Sartor A, Rello J, Tumbarello M.

J Clin Microbiol. 2013 Dec;51(12):4167-72. doi: 10.1128/JCM.01998-13. Epub 2013 Oct 9.

9.

Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU.

Nolla-Salas J, Sitges-Serra A, León-Gil C, Martínez-González J, León-Regidor MA, Ibáñez-Lucía P, Torres-Rodríguez JM.

Intensive Care Med. 1997 Jan;23(1):23-30.

PMID:
9037636
10.

Impact of first-line antifungal agents on the outcomes and costs of candidemia.

Ha YE, Peck KR, Joo EJ, Kim SW, Jung SI, Chang HH, Park KH, Han SH.

Antimicrob Agents Chemother. 2012 Jul;56(7):3950-6. doi: 10.1128/AAC.06258-11. Epub 2012 Apr 23.

11.

Design of antimicrobial stewardship care bundles on the high dependency unit.

Coll A, Kinnear M, Kinnear A.

Int J Clin Pharm. 2012 Dec;34(6):845-54. doi: 10.1007/s11096-012-9680-9. Epub 2012 Aug 3.

PMID:
22864866
12.

Candidemic complications in patients with intravascular catheters colonized with Candida species: an indication for preemptive antifungal therapy?

Leenders NH, Oosterheert JJ, Ekkelenkamp MB, De Lange DW, Hoepelman AI, Peters EJ.

Int J Infect Dis. 2011 Jul;15(7):e453-8. doi: 10.1016/j.ijid.2011.03.009. Epub 2011 May 6.

13.

Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study.

Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, Shorr AF.

BMC Infect Dis. 2010 Jun 3;10:150. doi: 10.1186/1471-2334-10-150.

14.

Candidemia outcomes not improved with statin use.

Welch ML, Liappis AP, Kan VL.

Med Mycol. 2013 Feb;51(2):219-22. doi: 10.3109/13693786.2012.692490. Epub 2012 Jun 4.

PMID:
22662759
15.

[Epidemiological and microbiological evaluation of nosocomial infections caused by Candida species].

Erdem F, Tuncer Ertem G, Oral B, Karakoç E, Demiröz AP, Tülek N.

Mikrobiyol Bul. 2012 Oct;46(4):637-48. Turkish.

PMID:
23188577
16.

The changing epidemiology of healthcare-associated candidemia over three decades.

Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M.

Diagn Microbiol Infect Dis. 2012 May;73(1):45-8. doi: 10.1016/j.diagmicrobio.2012.02.001.

PMID:
22578938
17.

Candida albicans versus non-albicans bloodstream infections: the comparison of risk factors and outcome.

Chi HW, Yang YS, Shang ST, Chen KH, Yeh KM, Chang FY, Lin JC.

J Microbiol Immunol Infect. 2011 Oct;44(5):369-75. doi: 10.1016/j.jmii.2010.08.010. Epub 2011 Jan 20.

18.

Implementing a pharmacist-led sequential antimicrobial therapy strategy: a controlled before-and-after study.

Dunn K, O'Reilly A, Silke B, Rogers T, Bergin C.

Int J Clin Pharm. 2011 Apr;33(2):208-14. doi: 10.1007/s11096-010-9475-9. Epub 2011 Jan 25.

PMID:
21744190
19.

Epidemiology of candidemia in patients with hematologic malignancies and solid tumours in Brazil.

Bergamasco MD, Garnica M, Colombo AL, Nucci M.

Mycoses. 2013 May;56(3):256-63. doi: 10.1111/myc.12013. Epub 2012 Oct 9.

PMID:
23043234
20.

Antifungal stewardship in invasive Candida infections.

Ruhnke M.

Clin Microbiol Infect. 2014 Jun;20 Suppl 6:11-8. doi: 10.1111/1469-0691.12622. Review.

Supplemental Content

Support Center